Nuclear Factor kappa B (NF-κB)

NF-κB is a protein complex inside cells that acts like a master switch, turning on genes that control inflammation, immune response, and cell survival. When asbestos fibers lodge in tissue, they trigger NF-κB activation in nearby cells, which keeps inflammation going for years or decades. This chronic, low-grade inflammation is one of the key biological steps linking asbestos exposure to mesothelioma and lung cancer.

Origin

NF-κB was discovered in 1986 by David Baltimore and Ranjan Sen at MIT, who identified it as a nuclear protein binding the kappa light-chain enhancer region of DNA in B lymphocytes, hence the name. It has since been recognized as one of the most important inflammatory signaling molecules in the human body.

Significance in Asbestos Context

Asbestos fibers cannot be broken down by the body, so immune cells (especially macrophages) repeatedly try and fail to digest them. This "frustrated phagocytosis" releases reactive oxygen species and TNF-alpha, which switch on NF-κB in mesothelial cells lining the lung and chest cavity. NF-κB then keeps those cells alive that would otherwise die from fiber damage, allowing genetic mutations to accumulate and eventually produce cancer. For patients, this mechanism is part of the scientific foundation showing how even modest asbestos exposures, decades earlier, can cause disease today; it also explains why anti-inflammatory drugs and NF-κB inhibitors are being studied as potential mesothelioma treatments.

Example Sentence

The oncologist explained that asbestos-driven activation of NF-κB had likely been quietly fueling inflammation in the patient's pleura for 30 years before the tumor was found.

Related Terms

TNF-alpha, Frustrated Phagocytosis, Chronic Inflammation, Mesothelioma, HMGB1, Reactive Oxygen Species

Notes

• If you are receiving treatment for mesothelioma or asbestos-related lung cancer, ask your oncologist whether any clinical trials targeting inflammation pathways (including NF-κB or HMGB1) are open and appropriate for your case.
• The chronic inflammation mechanism is well-accepted in the medical literature and supports the long latency period between exposure and diagnosis, important context if a defendant argues your exposure was "too long ago" to matter.
• Preserve any pathology reports or research-grade tissue samples; molecular markers of inflammation in your tumor tissue may become relevant for both treatment decisions and expert causation testimony.
• Some over-the-counter and prescription anti-inflammatories affect NF-κB; do not start or stop any medication without discussing it with your treating oncologist, as some can interfere with cancer therapies.